Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia

The treatment of chronic myeloid leukemia (CML) has been radically changed by the approval of tyrosine kinase inhibitors (TKIs), which target BCR-ABL1 kinase activity. CML is now managed as a chronic disease requiring long-term treatment and close molecular monitoring. It has been shown that in a su...

Descripción completa

Detalles Bibliográficos
Autores principales: Annunziata, Mario, Bonifacio, Massimiliano, Breccia, Massimo, Castagnetti, Fausto, Gozzini, Antonella, Iurlo, Alessandra, Pregno, Patrizia, Stagno, Fabio, Specchia, Giorgina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280484/
https://www.ncbi.nlm.nih.gov/pubmed/32582549
http://dx.doi.org/10.3389/fonc.2020.00883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280484/
https://www.ncbi.nlm.nih.gov/pubmed/32582549
http://dx.doi.org/10.3389/fonc.2020.00883

Ejemplares similares